Sana Biotechnology Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 424

Employees

  • Stock Symbol
  • SANA

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $8.45
  • (As of Monday Closing)

Sana Biotechnology General Information

Description

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.

Contact Information

Website
www.sana.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 188 East Blaine Street
  • Suite 400
  • Seattle, WA 98102
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sana Biotechnology Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.45 $8.29 $2.75 - $9.15 $1.85B 219M 3.29M -$1.43

Sana Biotechnology Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 549,386 379,399 2,418,328
Revenue 0 0 0 0
EBITDA (266,918) (257,613) (345,504) (280,131)
Net Income (275,581) (269,476) (355,928) (285,305)
Total Assets 631,440 822,720 1,129,407 730,296
Total Debt 96,864 108,253 110,943 71,909
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sana Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sana Biotechnology‘s full profile, request access.

Request a free trial

Sana Biotechnology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Sana Biotechnology‘s full profile, request access.

Request a free trial

Sana Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to t
Biotechnology
Seattle, WA
424 As of 2023
00.000
00000000 00.000

000000

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000000000000
Berkeley, CA
000 As of 0000
00000
00000000 00000

000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
000000000000000
Brentford, United Kingdom
00000 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sana Biotechnology Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Caribou Biosciences Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
GSK Corporation Brentford, United Kingdom 00000 000.00 000000000 000.00
Novartis Corporation Basel, Switzerland 00000 0000 000000000 0000
Bristol-Myers Squibb Private Debt Financed Princeton, NJ 00000 000.00 000000000 000.00
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 000.00 000000000 000.00
You’re viewing 5 of 9 competitors. Get the full list »

Sana Biotechnology Patents

Sana Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022325232-A1 Genetically modified primary cells for allogeneic cell therapy Pending 11-Aug-2021 0000000000
AU-2022325955-A1 Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions Pending 11-Aug-2021 000000000
AU-2022326565-A1 Genetically modified cells for allogeneic cell therapy Pending 11-Aug-2021 0000000000
AU-2022325231-A1 Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions Pending 11-Aug-2021 000000000
US-20240010988-A1 Genetically modified primary cells for allogeneic cell therapy Pending 11-Aug-2021 C12N5/0676
To view Sana Biotechnology’s complete patent history, request access »

Sana Biotechnology Executive Team (15)

Name Title Board Seat Contact Info
Steven Harr MD Founder, President & Chief Executive Officer
Douglas Williams Ph.D Executive Vice President & President
Nate Hardy Chief Financial Officer
Christian Hordo Executive Vice President & Executive
Farah Anwar Head, Development Operations, Inclusion, Diversity and Equity Leader & Vice President
You’re viewing 5 of 15 executive team members. Get the full list »

Sana Biotechnology Board Members (15)

Name Representing Role Since
Alise Reicin MD Sana Biotechnology Board Member 000 0000
Donald Payan MD Sana Biotechnology Board Member 000 0000
Douglas Cole MD Flagship Pioneering Board Member 000 0000
Geoffrey von Maltzahn Ph.D Flagship Pioneering Co-Founder & Board Member 000 0000
Hans Bishop Sana Biotechnology Chairman 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Sana Biotechnology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sana Biotechnology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sana Biotechnology‘s full profile, request access.

Request a free trial

Sana Biotechnology Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Repairon 01-Jan-2021 0000 00000 Other Healthcare Technology Systems
Oscine Therapeutics 30-Oct-2020 0000000000 Discovery Tools (Healthcare)
Cytocardia 12-Nov-2019 0000000000 000 Biotechnology
Oscine Therapeutics 11-Jun-2019 00000 0000 Discovery Tools (Healthcare)
Cobalt Biomedicine 01-Feb-2019 Merger/Acquisition 00000 Drug Delivery 000000 00
To view Sana Biotechnology’s complete investments and acquisitions history, request access »

Sana Biotechnology ESG

Risk Overview

Risk Rating

Updated May, 19, 2023

26.77 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,605

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 870

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 386

Rank

00.00

Percentile

To view Sana Biotechnology’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »